Independent Power Producers
Compare Stocks
4 / 10Stock Comparison
KEN vs TEVA vs VTRS vs AMTD
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Asset Management
KEN vs TEVA vs VTRS vs AMTD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Independent Power Producers | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Asset Management |
| Market Cap | $4.52B | $41.93B | $20.25B | $7M |
| Revenue (TTM) | $775M | $17.35B | $14.56B | $54M |
| Net Income (TTM) | $495M | $1.56B | $-296M | $188M |
| Gross Margin | 17.1% | 52.1% | 34.4% | 45.2% |
| Operating Margin | 5.0% | 13.2% | 1.0% | 48.2% |
| Forward P/E | 7.6x | 14.5x | 7.1x | 0.3x |
| Total Debt | $1.28B | $17.38B | $14.70B | $283M |
| Cash & Equiv. | $1.02B | $3.56B | $1.35B | $63M |
KEN vs TEVA vs VTRS vs AMTD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kenon Holdings Ltd. (KEN) | 100 | 422.8 | +322.8% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
| Viatris Inc. (VTRS) | 100 | 101.9 | +1.9% |
| AMTD IDEA Group (AMTD) | 100 | 2.7 | -97.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KEN vs TEVA vs VTRS vs AMTD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
KEN is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 8.6%, EPS growth 356.6%, 3Y rev CAGR 15.5%
- 12.6% 10Y total return vs TEVA's -28.3%
- 8.6% revenue growth vs AMTD's -55.9%
- +194.0% vs AMTD's +5.0%
TEVA plays a supporting role in this comparison — it may shine differently against other peers.
VTRS lags the leaders in this set but could rank higher in a more targeted comparison.
AMTD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.06, yield 36.7%
- Lower volatility, beta 0.06, Low D/E 16.7%, current ratio 10.62x
- Beta 0.06, yield 36.7%, current ratio 10.62x
- Lower P/E (0.3x vs 7.1x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.6% revenue growth vs AMTD's -55.9% | |
| Value | Lower P/E (0.3x vs 7.1x) | |
| Quality / Margins | 94.4% margin vs VTRS's -2.0% | |
| Stability / Safety | Beta 0.06 vs TEVA's 1.13, lower leverage | |
| Dividends | 36.7% yield, 1-year raise streak, vs KEN's 4.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +194.0% vs AMTD's +5.0% | |
| Efficiency (ROA) | 11.4% ROA vs VTRS's -0.8%, ROIC 1.2% vs -6.6% |
KEN vs TEVA vs VTRS vs AMTD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
KEN vs TEVA vs VTRS vs AMTD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMTD leads in 2 of 6 categories
TEVA leads 1 • KEN leads 0 • VTRS leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — KEN and AMTD each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 320.9x AMTD's $54M. AMTD is the more profitable business, keeping 94.4% of every revenue dollar as net income compared to VTRS's -2.0%. On growth, KEN holds the edge at +8.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $775M | $17.3B | $14.6B | $54M |
| EBITDAEarnings before interest/tax | $122M | $3.3B | $2.3B | $263M |
| Net IncomeAfter-tax profit | $495M | $1.6B | -$296M | $188M |
| Free Cash FlowCash after capex | $222M | $1.2B | $1.7B | $45M |
| Gross MarginGross profit ÷ Revenue | +17.1% | +52.1% | +34.4% | +45.2% |
| Operating MarginEBIT ÷ Revenue | +5.0% | +13.2% | +1.0% | +48.2% |
| Net MarginNet income ÷ Revenue | +63.8% | +9.0% | -2.0% | +94.4% |
| FCF MarginFCF ÷ Revenue | +28.6% | +6.8% | +11.7% | +9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.3% | +2.3% | +8.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -95.3% | +72.2% | +105.9% | -88.3% |
Valuation Metrics
AMTD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 0.3x trailing earnings, AMTD trades at a 99% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, AMTD's 6.9x EV/EBITDA is more attractive than VTRS's 248.5x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4.5B | $41.9B | $20.2B | $7M |
| Enterprise ValueMkt cap + debt − cash | $4.8B | $55.8B | $33.6B | $228M |
| Trailing P/EPrice ÷ TTM EPS | 7.64x | 30.01x | -5.80x | 0.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.55x | 7.12x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 33.93x | 17.65x | 248.54x | 6.93x |
| Price / SalesMarket cap ÷ Revenue | 6.01x | 2.43x | 1.42x | 0.14x |
| Price / BookPrice ÷ Book value/share | 1.72x | 5.34x | 1.38x | 0.01x |
| Price / FCFMarket cap ÷ FCF | — | 36.52x | 10.45x | 1.44x |
Profitability & Efficiency
Evenly matched — TEVA and AMTD each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-2 for VTRS. AMTD carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), KEN scores 8/9 vs AMTD's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +19.1% | +20.7% | -2.0% | +12.9% |
| ROA (TTM)Return on assets | +11.4% | +3.9% | -0.8% | +10.8% |
| ROICReturn on invested capital | +1.2% | +7.7% | -6.6% | +1.2% |
| ROCEReturn on capital employed | +1.2% | +8.0% | -8.1% | +1.6% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 8 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.48x | 2.20x | 1.00x | 0.17x |
| Net DebtTotal debt minus cash | $264M | $13.8B | $13.4B | $221M |
| Cash & Equiv.Liquid assets | $1.0B | $3.6B | $1.3B | $63M |
| Total DebtShort + long-term debt | $1.3B | $17.4B | $14.7B | $283M |
| Interest CoverageEBIT ÷ Interest expense | 0.52x | 2.51x | -0.51x | 17.18x |
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $256 for AMTD. Over the past 12 months, KEN leads with a +194.0% total return vs AMTD's +5.0%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs AMTD's -40.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +34.0% | +16.3% | +40.5% | +2.9% |
| 1-Year ReturnPast 12 months | +194.0% | +104.6% | +107.8% | +5.0% |
| 3-Year ReturnCumulative with dividends | +246.9% | +297.5% | +91.8% | -78.8% |
| 5-Year ReturnCumulative with dividends | +240.6% | +246.2% | +40.3% | -97.4% |
| 10-Year ReturnCumulative with dividends | +1256.7% | -28.3% | -51.5% | -91.4% |
| CAGR (3Y)Annualised 3-year return | +51.4% | +58.4% | +24.2% | -40.4% |
Risk & Volatility
Evenly matched — VTRS and AMTD each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMTD is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTRS currently trades 99.7% from its 52-week high vs AMTD's 63.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.13x | 0.99x | 0.06x |
| 52-Week HighHighest price in past year | $95.93 | $37.35 | $17.45 | $1.65 |
| 52-Week LowLowest price in past year | $30.42 | $14.99 | $8.19 | $0.87 |
| % of 52W HighCurrent price vs 52-week peak | +90.3% | +96.4% | +99.7% | +63.6% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 73.5 | 75.7 | 48.3 |
| Avg Volume (50D)Average daily shares traded | 26K | 6.6M | 10.6M | 24K |
Analyst Outlook
AMTD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: KEN as "Hold", TEVA as "Buy", VTRS as "Hold". Consensus price targets imply 8.3% upside for TEVA (target: $39) vs -12.3% for VTRS (target: $15). For income investors, AMTD offers the higher dividend yield at 36.70% vs VTRS's 2.76%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | — |
| Price TargetConsensus 12-month target | — | $39.00 | $15.25 | — |
| # AnalystsCovering analysts | 1 | 46 | 12 | — |
| Dividend YieldAnnual dividend ÷ price | +4.4% | — | +2.8% | +36.7% |
| Dividend StreakConsecutive years of raises | 1 | 1 | 0 | 1 |
| Dividend / ShareAnnual DPS | $3.80 | — | $0.48 | $0.39 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% | +2.5% | 0.0% |
AMTD leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). TEVA leads in 1 (Total Returns). 3 tied.
KEN vs TEVA vs VTRS vs AMTD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KEN or TEVA or VTRS or AMTD a better buy right now?
For growth investors, Kenon Holdings Ltd.
(KEN) is the stronger pick with 8. 6% revenue growth year-over-year, versus -55. 9% for AMTD IDEA Group (AMTD). AMTD IDEA Group (AMTD) offers the better valuation at 0. 3x trailing P/E, making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KEN or TEVA or VTRS or AMTD?
On trailing P/E, AMTD IDEA Group (AMTD) is the cheapest at 0.
3x versus Teva Pharmaceutical Industries Limited at 30. 0x. On forward P/E, Viatris Inc. is actually cheaper at 7. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — KEN or TEVA or VTRS or AMTD?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to -97. 4% for AMTD IDEA Group (AMTD). Over 10 years, the gap is even starker: KEN returned +1257% versus AMTD's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KEN or TEVA or VTRS or AMTD?
By beta (market sensitivity over 5 years), AMTD IDEA Group (AMTD) is the lower-risk stock at 0.
06β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 1690% more volatile than AMTD relative to the S&P 500. On balance sheet safety, AMTD IDEA Group (AMTD) carries a lower debt/equity ratio of 17% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — KEN or TEVA or VTRS or AMTD?
By revenue growth (latest reported year), Kenon Holdings Ltd.
(KEN) is pulling ahead at 8. 6% versus -55. 9% for AMTD IDEA Group (AMTD). On earnings-per-share growth, the picture is similar: Kenon Holdings Ltd. grew EPS 356. 6% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, KEN leads at 15. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KEN or TEVA or VTRS or AMTD?
AMTD IDEA Group (AMTD) is the more profitable company, earning 94.
4% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 94. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMTD leads at 48. 2% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KEN or TEVA or VTRS or AMTD more undervalued right now?
On forward earnings alone, Viatris Inc.
(VTRS) trades at 7. 1x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TEVA: 8. 3% to $39. 00.
08Which pays a better dividend — KEN or TEVA or VTRS or AMTD?
In this comparison, AMTD (36.
7% yield), KEN (4. 4% yield), VTRS (2. 8% yield) pay a dividend. TEVA does not pay a meaningful dividend and should not be held primarily for income.
09Is KEN or TEVA or VTRS or AMTD better for a retirement portfolio?
For long-horizon retirement investors, Kenon Holdings Ltd.
(KEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 4. 4% yield, +1257% 10Y return). Both have compounded well over 10 years (KEN: +1257%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KEN and TEVA and VTRS and AMTD?
These companies operate in different sectors (KEN (Utilities) and TEVA (Healthcare) and VTRS (Healthcare) and AMTD (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: KEN is a small-cap deep-value stock; TEVA is a mid-cap quality compounder stock; VTRS is a mid-cap quality compounder stock; AMTD is a small-cap deep-value stock. KEN, VTRS, AMTD pay a dividend while TEVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.